TENX Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. (TENX) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -88.0% since its last earnings release on July 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Tenax Therapeutics, Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company. The Company is engaged in developing & commercializing pharmaceutical products for critical care patients. Its products include; Levosimendan and Oxycyte.
Sector
Healthcare
Industry
Biotechnology